2023 (43 POSTS)

Borghoff SJ, Cohen SS, Jiang X, Lea IA, Klaren WD, Chappell GA, Britt JK, Rivera BN, Choksi NY, Wikoff DS. 2023. Updated systematic assessment of human, animal and mechanistic evidence demonstrates lack of human carcinogenicity with consumption of aspartame. Food Chem Toxicol 172:113549, online ahead of print.

View Abstract

Godínez-Oviedo A, Sampedro F, Bowman JP, Garcés-Vega FJ, Hernández-Iturriaga M. 2023. Genotypic and phenotypic quantitative microbial risk assessment model of human salmonellosis related to the consumption of chicken meat in the central region of Mexico. Food Res Int 162(A):111901, https://doi.org/10.1016/j.foodres.2022.111901.

View Abstract

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, Liu Y, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant DVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcomes Res 23(2):225-230.

View Abstract

2022 (62 POSTS)

Doepker C, Movva N, Cohen SS, Wikoff DS. 2022. Benefit-risk of coffee consumption and all-cause mortality: A systematic review and disability adjusted life year analysis. Food Chem Toxicol 170:113472, doi: 10.1016/j.fct.2022.113472.

View Abstract

Boles C, Zisook R, Buerger AN, Hamaji C, Mathis C, Lauer D, et al. 2022. Semi-quantitative microbial risk assessment: a narrative review and proposed framework for health and safety practitioners. Journal of Public Health and Emergency 6:34.

View Abstract

Broome CM, Hooda N, Su J, Jiang X, Nicholson G, Frankenfeld CL, Iglesias-Rodriguez M, Fryzek J, Patel Parija. 2022. Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States. PLOS ONE open access, https://doi.org/10.1371/journal.pone.0276617.

View Abstract

Cardosi L, Rau R, Emdem MR, Kemp R, Minshall M, Pontenani F, Provision S, Sacks N. 2022. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Value in Health 25(12). Supplement. S1:S546, DOI: 10.1016/j.jval.2022.09.437, online article.

View Abstract

Villeneuve DL, Blackwell BR, Blanksma C, Cavallin JE, Cheng W, Conolly R, Conrow K, Feifarek DJ, Heinis L, Jensen KM, Kahl MD, Milsk RY, Poole ST, Randolph EC, Saari TW, Watanabe K, Ankley GT. 2022. Case study in 21st century ecotoxicology: Using in vitro aromatase inhibition data to predict reproductive outcomes in fish, in vivo. Environ Toxicol Chem 42(1):100–116.

View Abstract

Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, Taioli E, Fryzek J. 2022. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS One 17(8):e0271339, doi: 10.1371/journal.pone.0271339. PMID: 36040901; PMCID: PMC9426882.

View Abstract

Cohen SS, Bylsma LC, Movva N, Alexander DD. 2022. Theoretical attributable risk analysis and Disability Adjusted Life Years (DALYs) based on increased dairy consumption. BMC Public Health 22(1):1625, doi: 10.1186/s12889-022-14042-7.

View Abstract

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4:937168, https://doi.org/10.3389/ftox.2022.937168.

View Abstract

Goyak KO, Sarang SS, Franzen A, Borghoff SJ, Ryman-Rasumssen JP. 2022. Adverse outcome pathway (AOP): α2u-globulin nephropathy and kidney tumors in male rats. Crit Rev Toxicol 52(5):345-357; doi: 10.1080/10408444.2022.2082269. PMID: 35862579.

View Abstract

Lynch HN, Lauer DJ, Thompson WJ, Leleck O, Freid RD, Collins J, Chen K, et al. 2022. Systematic review of the scientific evidence of the pulmonary carcinogenicity of talc. Front Public Health 10:989111; doi: 10.3389/fpubh.2022.989111.

View Abstract

Campion SN, Potter DM, Bowman CJ, Catlin NR, Davis S, Millard C, Nowland WS, Stethem CM, Hollingshead BD, Radi ZA, Coder PS, Cappon GD. 2022. Lack of effects on bone growth and development following administration of tofacitinib, a JAK inhibitor, to juvenile rats and evaluation of the association between offspring growth and femur length. Reprod Toxicol 113:35–41, DOI: 10.1016/j.reprotox.2022.08.002, article online

View Abstract

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer.  Adv Ther 39(6):2778–2795. doi:10.1007/s12325-022-02141-1.

View Abstract

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338. doi: 10.1007/s00520-022-06967-x.

View Abstract

Hulsey A, Cekola P, Henrikson A, Reichert H, Cohen SS, Torres KA. 2022. Growth and tolerance with an amino acid based enteral formula: A two-year retrospective study from a children’s rehabilitation hospital. J Clin Nutr Dietet 8(8):181.

View Abstract

Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. Mortality associated with respiratory syncytial virus, bronchiolitis, and influenza among infants in the United States: A birth cohort study from 1998 to 2018. J Infect Dis 226(Suppl 2):S246–S254.

View Abstract

Bylsma LC, Suh M, Movva N, Fryzek JP, Nelson CB. 2022. Mortality among United States infants and children under 5 years of age with respiratory syncytial virus and bronchiolitis: A systematic literature review. J Infect Dis 226(Suppl 2):S267–S281.

View Abstract

Movva N, Suh M, Bylsma LC, Fryzek JP, Nelson CB. 2022. Systematic literature review of respiratory syncytial virus laboratory testing practices and incidence in United States infants and children <5 years of age. J Infect Dis 226(Suppl 2):S213–S224.

View Abstract